Status:
COMPLETED
Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
This study aims to assess the effect and breakdown of lysine administration, specifically examining whether it leads to increased plasma 2-AAA in healthy humans.
Detailed Description
The purpose of this study is to investigate a novel biomarker, α-aminoadipic acid (2-AAA), which may influence the risk of diabetes. 2-AAA has been identified as a novel predictor of diabetes developm...
Eligibility Criteria
Inclusion
- Prior participant in 2-AAA Dietary study.
Exclusion
- Newly diagnosed disease, including cardiovascular, renal, liver disease, or Diabetes mellitus.
- Individuals who are pregnant or lactating.
- Inability to provide written or electronic informed consent.
- Inability to fast for 8 hours.
Key Trial Info
Start Date :
March 9 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 27 2023
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT05210504
Start Date
March 9 2022
End Date
January 27 2023
Last Update
June 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37212